Related Experiment Video
Updated: Apr 9, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with
Leila Mehrnoush1,2, Seyed-Moayed Alavian1,2, Heidar Sharafi1,2,3
1a Iran Hepatitis Network , Tehran , IR Iran.
Insights
Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) combination therapy shows higher efficacy in hemophilic children with chronic hepatitis C than in adults. This treatment achieved a significantly higher sustained virological response (SVR) rate in pediatric patients.
Area of Science:
- Hepatology
- Pediatric Hematology
- Virology
Background:
- Chronic hepatitis C (HCV) infection poses a significant health challenge, particularly in hemophilic patients who may have received contaminated blood products.
- Limited data exists on the effectiveness of Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) combination therapy for HCV in pediatric hemophilic populations.
Purpose of the Study:
- To assess the efficacy of Peg-IFN and RBV combination therapy in hemophilic children with chronic hepatitis C.
- To compare treatment outcomes in pediatric hemophilic patients with those in adult hemophilic patients.
Main Methods:
- A case-control study involving 31 treatment-naive pediatric hemophilic patients (under 16 years) and 62 treatment-naive adult hemophilic patients with HCV genotypes 1 or 3.
- Patients were matched based on HCV genotype, viral load, and rs12979860 polymorphism.
- Both groups received Peg-IFN and RBV for 24-48 weeks.
Main Results:
- Sustained virological response (SVR) was achieved in 83.9% of pediatric patients compared to 62.9% of adult patients (P=0.05).
- Early virological response was a significant predictor of SVR in both age groups.
- No significant difference in SVR rates was observed based on HCV genotype, viral load, or rs12979860 polymorphism.
Conclusions:
- Peg-IFN and RBV combination therapy demonstrates superior efficacy in achieving SVR in hemophilic children compared to adult hemophilic patients with chronic hepatitis C.
- The findings support the use of this therapeutic regimen in pediatric hemophilic populations, with early virological response as a key indicator of successful treatment.
Abstract:
Scarce data is available on the efficacy of Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) combination therapy in hemophilic children with chronic hepatitis C. The aim of this study was to evaluate the efficacy of Peg-IFN and RBV combination therapy for hemophilic children infected with hepatitis C virus (HCV) in comparison with adult hemophilic patients with chronic hepatitis C. A case-control study comprised 31 pediatric hemophilic patients ages under 16 years with previously untreated HCV genotype-1 or -3 infection as the case group and 62 treatment naive adult hemophilic patients with chronic HCV infection as the control group. Case and control groups were matched case by case according to HCV genotype, HCV RNA level and rs12979860 polymorphism. All patients in the case and control groups were treated with Peg-IFN and RBV for 24-48 weeks according to HCV genotype. Sustained virological response (SVR) was achieved in 26 (83.9%) pediatric patients and in 39 (62.9%) of adult patients (P = 0.05, OR = 3.07, 95%CI = 1.03-9.09). The rate of SVR was not different according to HCV genotype, HCV RNA level, and rs12979860 polymorphism in both studied groups whereas achieving early virological response was associated with achievement of SVR in both groups. The efficacy of Peg-IFN and RBV combination therapy in hemophilic children with chronic hepatitis C is higher than that of adult hemophilic patients.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis